Dual antiplatelet therapy after stroke ‘beneficial up to 90 days’
An evidence review shows that longer duration of dual therapy is not superior to single therapy and increases the risk of major bleeding
Dual antiplatelet therapy reduces the risk of recurrent stroke more than single antiplatelet therapy but only when initiated promptly and continued for less than 90 days, a review shows.
The systematic review and meta-analysis, by a committee of the American Heart Association and the American Stroke Association, was commissioned to provide evidence for a 2021 update of guidelines on prevention of recurrent stroke.
